OPC Pharmaceutical Joint Stock Company

HOSE:OPC Stock Report

Market Cap: ₫1.5t

OPC Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

OPC Pharmaceutical has been growing earnings at an average annual rate of 3.2%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 0.8% per year. OPC Pharmaceutical's return on equity is 12.1%, and it has net margins of 9.1%.

Key information

3.2%

Earnings growth rate

3.2%

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth rate0.8%
Return on equity12.1%
Net Margin9.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How OPC Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

HOSE:OPC Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24951,22586,159324,8930
30 Jun 24979,66895,290334,3040
31 Mar 241,027,903103,420347,7790
31 Dec 231,004,887104,691332,3110
30 Sep 23983,349115,809325,1790
30 Jun 231,039,274121,611351,2200
31 Mar 23989,310114,485306,4630
31 Dec 221,171,614128,118355,0730
30 Sep 221,225,353129,058324,6160
30 Jun 221,245,135126,068309,9180
31 Mar 221,225,233115,178344,8550
31 Dec 211,123,728112,961313,5160
30 Sep 211,062,751105,759304,7770
30 Jun 21978,15194,020283,2330
31 Mar 21977,76398,960264,0800
31 Dec 20965,59194,798257,0490
30 Sep 20906,63885,631245,6980
30 Jun 20961,40492,235262,9370
31 Mar 201,011,61495,729292,4330
31 Dec 19989,39090,392305,6750
30 Sep 191,021,06095,010321,1850
30 Jun 19977,31888,435315,2550
31 Mar 19963,91087,648316,5730
31 Dec 181,002,47888,013334,0630
30 Sep 18964,91582,013325,2270
30 Jun 18968,35384,157329,4350
31 Mar 18946,44680,677318,2770
31 Dec 17944,85078,262333,7010
30 Sep 17928,09080,059325,4530
30 Jun 17901,04375,868319,8010
31 Mar 17870,91072,526321,5640
31 Dec 16790,40570,251284,9700
30 Sep 16718,86665,252274,6810
30 Jun 16684,76161,213265,4970
31 Mar 16672,67062,380260,8810
31 Dec 15663,21363,238252,8170
30 Sep 15658,24468,056254,0060
30 Jun 15634,70262,077252,0520
31 Mar 15630,43453,260233,7590
31 Dec 14612,47558,909219,5700
30 Sep 14632,80250,617216,4080
30 Jun 14623,46553,294217,3860
31 Mar 14604,17364,489219,1640
31 Dec 13563,81956,254202,0550

Quality Earnings: OPC has high quality earnings.

Growing Profit Margin: OPC's current net profit margins (9.1%) are lower than last year (11.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: OPC's earnings have grown by 3.2% per year over the past 5 years.

Accelerating Growth: OPC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: OPC had negative earnings growth (-25.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13%).

Return on Equity

High ROE: OPC's Return on Equity (12.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 23:23
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OPC Pharmaceutical Joint Stock Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution